生物技术公司FibroBiologics已顺利完成针对候选药物Cywc628的一期/二期临床试验中心启动流程。该试验旨在评估Cywc628在治疗难治性糖尿病足溃疡方面的安全性与有效性。这一关键进展为后续患者入组及临床研究开展奠定了坚实基础。
生物技术公司FibroBiologics已顺利完成针对候选药物Cywc628的一期/二期临床试验中心启动流程。该试验旨在评估Cywc628在治疗难治性糖尿病足溃疡方面的安全性与有效性。这一关键进展为后续患者入组及临床研究开展奠定了坚实基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.